2026年6月5日，翰思艾泰生物医药科技（武汉）股份有限公司（翰思艾泰-B，股票代码：03378）发布公告，披露了当日于香港联合交易所回购股份的相关信息。公司于2026年6月5日回购普通股H股3.91万股，约占回购前已发行股份总数的0.029%。本次回购的每股价格介于26.52港元至27.98港元之间，合计支付对价1,064,884港元，折合约106.49万港元。
公告显示，截至回购完成后，公司已发行股份数量从135,213,130股降至135,174,030股，库藏股数量则由1,005,700股增加至1,044,800股。公司本次回购基于2026年2月12日通过的购回授权，该授权的可回购股份总数为13,621,883股。截至目前，公司累计在香港联交所及其他交易平台购回的股份数量为1,044,800股，占购回授权当日已发行股份数目的约0.767%。
公司同时确认，已遵守香港联交所证券上市规则及相关法律法规的规定。此次公告由公司董事长兼执行董事张发明签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.